R andomized clinical trials have consistently shown that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) reduce cardiovascular event rates. [1] [2] [3] [4] [5] [6] [7] [8] [9] The favorable effects of statins extend across a range of levels of low-density lipoprotein (LDL) cholesterol, with no apparent lower threshold for a benefit. 3, 9, 10 In parallel, imaging trials have shown that intensive statin regimens slow the progression of coronary atherosclerosis and may even result in disease regression in some patients. 11, 12 Accordingly, guidelines for cardiovascular disease prevention have increasingly emphasized that lowering LDL cholesterol levels with statins is the primary goal of lipid-modulating therapy. 13, 14 Available statins differ considerably in their ability to reduce atherogenic lipid levels and raise the level of high-density lipoprotein (HDL) cholesterol. Atorvastatin and rosuvastatin are the most effective statins for lowering LDL cholesterol levels, yielding average reductions that approach 50% for atorvastatin and exceed 50% for rosu va stat in. 15, 16 Direct comparisons have shown greater reductions in LDL cholesterol levels and greater increases in HDL cholesterol levels with rosuva statin, [15] [16] [17] but the clinical consequences of these differences remain unclear. Although studies comparing lipid lowering by these two statins have been carried out, to our knowledge, no randomized clinical trials have directly compared their effects on disease progression or cardiovascular event rates.
Intravascular ultrasonography can be used to obtain precise and reproducible serial measurements of atherosclerotic plaques in the coronary arteries. 18 The use of intravascular ultrasonography in clinical trials permits examination of the effects of antiatherosclerotic therapies on the course of coronary artery disease. 11, 12, [19] [20] [21] [22] [23] [24] [25] [26] A metaanalysis of the results of such trials suggested that the combined effects of statins -lowering LDL cholesterol levels and increasing HDL cholesterol levels -slow the progression of coronary plaques. 27 We compared the highest doses of two intensive statin regimens to determine whether there were discernible differences in their effects on the progression of coronary atherosclerosis.
Me thods

Study Design
The Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin versus Ator vastat in (SATURN) was a prospective, randomized, multicenter, double-blind clinical trial. 28 Randomization was stratified according to geographic region. The trial was designed by the Cleveland Clinic Coordinating Center for Clinical Research in collaboration with the sponsor (AstraZeneca Pharmaceuticals). The institutional review board at each site approved the protocol (available with the full text of this article at NEJM.org), and all patients provided written informed consent.
Patients 18 to 75 years of age were eligible if they had at least one vessel with 20% stenosis on clinically indicated coronary angiography and a target vessel for imaging with less than 50% obstruction. Patients who had not been treated with a statin in the preceding 4 weeks were required to have an LDL cholesterol level at entry that was higher than 100 mg per deciliter (2.6 mmol per liter); those who had received such treatment were required to have a level higher than 80 mg per deciliter (2.1 mmol per liter). Patients were excluded if they had received intensive lipid-lowering therapy for more than 3 months in the previous year or had uncontrolled hypertension, heart failure, renal dysfunction, or liver disease (see the Supplementary Appendix, available at NEJM.org).
Patients who met the inclusion criteria underwent preliminary randomization by means of an interactive voice-response system and were randomly assigned in a 1:1 ratio to receive either ator va stat in, at a dose of 40 mg daily, or rosu vastat in, at a dose of 20 mg daily, for 2 weeks to ascertain side effects and compliance. Patients with an LDL cholesterol level of less than 116 mg per deciliter (3.0 mmol per liter) and a triglyceride level of less than 500 mg per deciliter (5.6 mmol per liter) after 2 weeks again underwent randomization in a 1:1 ratio, this time to full-dose treatment with ator va stat in (80 mg daily) or rosu vastat in (40 mg daily) for 104 weeks. A clinical events committee whose members were unaware of the treatment assignments adjudicated cardiovascular events at a central location.
All the academic authors collected, held, and analyzed the data and made the decision to submit the manuscript for publication. The first academic author wrote the manuscript and vouches for the accuracy and completeness of the data and the analyses. The study was conducted in accordance with the protocol. Although the steering committee and coordinating center had confidentiality agreements with the sponsor, the study contract specified that a copy of the study database be pro- vided to the coordinating center for independent analysis and granted the academic authors unrestricted rights to publish the results.
Acquisition and Analysis of Ultrasonographic Images
Intravascular ultrasonography was performed at baseline, after coronary angiographic assessments had been completed. Previous reports have described the methods used for image acquisition and analysis. 11, 12, [19] [20] [21] [22] [23] [24] Imaging was performed in a single artery, and the results were screened by a core laboratory. Patients who met prespecified requirements for image quality were then eligible for randomization. After 104 weeks of treatment, patients underwent a second ultrasonographic examination of the same artery. Using digitized images, personnel who were unaware of the treatment assignments and the temporal sequence of paired images measured the lumen and external elastic membrane within a matched arterial segment. The accuracy and reproducibility of this method have been reported previously. The primary efficacy end point, percent atheroma volume (PAV), was calculated as follows:
where EEM area is the cross-sectional area of the external elastic membrane, and lumen area is the cross-sectional area of the lumen. For PAV, the summation of the EEM area minus the lumen area is performed first. This value is then divided by the summation of the EEM area, which is finally multiplied by 100. The change in PAV was calculated as the PAV at 104 weeks minus the PAV at baseline. A secondary efficacy end point, normalized total atheroma volume (TAV), was calculated as follows: For TAV, the summation of the EEM area minus the lumen area is performed first. This value is divided by the number of images in the pullback and then multiplied by the median number of images in the cohort. The average plaque area in the pullback was multiplied by the median number of images analyzed in the entire cohort to compensate for differences in segment length between subjects. The efficacy end point of change in normalized TAV was calculated as the TAV at 104 weeks minus the TAV at baseline. Regression was defined as a decrease in PAV or TAV from baseline.
Biochemical Assessments
During treatment, levels of HDL and LDL cholesterol and triglycerides were measured at 6, 12, 18, and 24 months. Levels of C-reactive protein were measured at 12 and 24 months.
Statistical Analysis
For continuous variables with an approximately normal distribution, means (±SD) are reported. For variables not distributed normally, medians and interquartile ranges are reported. Intravascular ultrasonographic efficacy end points are reported as medians, with distribution-free 95% confidence intervals, and treatment groups were compared with the use of analysis of covariance on ranktransformed data after adjustment for baseline values and geographic region. Lipoprotein levels during treatment are reported as least-squares means (±SE) from analyses of covariance controlled for treatment group and geographic region. For the change in the primary efficacy end point, PAV, a sample of 450 patients in each treatment group was required for 90% power at a two-sided alpha level of 0.05 to detect a nominal treatment difference of 0.65%, assuming a standard deviation of 3.0%. On the basis of an assumed withdrawal rate of 30%, 1300 patients were required for randomization. All reported P values are two-sided. The statisticalanalysis plan is available, along with the protocol, at NEJM.org.
R e sult s
Characteristics of the Patients
From January 22, 2008, through June 12, 2009, a total of 1578 patients at 208 centers were randomly assigned to 2 weeks of treatment with halfmaximal doses of either ator va stat in or rosu vastat in. After this run-in period, 1385 patients were randomly assigned to full-dose treatment: 691 to the ator va stat in group and 694 to the rosuva stat in group. After 104 weeks of treatment, 1039 patients (75%) remained in the study and underwent repeat intravascular ultrasonography, so that the findings on follow-up imaging could be compared with the baseline findings. Of these patients, 519 were in the ator va stat in group, and 520 were in the rosu va stat in group. There were no significant differences in demographic characteristics or in baseline medication use or laboratory values between the two treatment groups (Table 1) . Similarly, demographic and baseline characteristics did not differ significantly between patients who completed the study and those who did not.
Biochemical Measurements
It was deemed ethically inappropriate to discontinue statin treatment in the patients who were receiving statin treatment before randomization. Accordingly, the percentage changes in lipid levels could not be calculated. , and a smaller proportion of rosuvastatin-treated patients whose LDL cholesterol levels remained higher than the current treatment goal of 100 mg per deciliter (2.6 mmol per liter) (4.6%, vs. 7.7% with ator va stat in; P = 0.04). Median C-reactive protein levels during treatment were 1.0 mg per liter (interquartile range, 0.5 to 2.0) in the ator va stat in group and 1.1 mg per liter (interquartile range, 0.5 to 2.4) in the rosuvastatin group (P = 0.05). For TAV, a significantly greater proportion of rosuvastatin-treated patients had disease regression (71.3%, vs. 64.7% with ator va stat in; P = 0.02). There was statistical heterogeneity between prespecified subgroups for the primary end point, with greater regression of PAV with rosuvastatin, as compared with ator va stat in, in women (−1.76% vs. −0.71%, P = 0.01) and in patients with higher baseline levels of HDL cholesterol (−1.41% vs. −0.61%, P = 0.02) and those with higher baseline levels of LDL cholesterol (−1.47% vs. −1.00%, P = 0.02) (Fig. 1) .
Efficacy End Points
Greater regression was also observed with rosuvastatin in patients who had HDL cholesterol levels above the mean (−1.44%, vs. −0.63% with ator vastat in; P = 0.03). Table 4 shows centrally adjudicated clinical events, laboratory abnormalities, and reasons for study discontinuation. The frequency of cardiovascular events was similar in the two groups. The rate of abnormal laboratory values was low. A higher incidence of elevated alanine aminotransferase levels was observed in the ator va stat in group (2.0%, vs. 0.7% with rosuvastatin; P = 0.04), and a higher incidence of proteinuria was observed in the rosuvastatin group (3.8%, vs. 1.7% with ator va stat in; P = 0.02). Glycated hemoglobin levels did not change significantly in either group.
Discussion
This study compared the effects on the progression of coronary atherosclerosis of the highest doses of ator va stat in and rosuvastatin, two of the most intensive statin regimens used in clinical practice today. Very low LDL cholesterol levels were achieved in both treatment groups, with mean values of less than or equal to 70 mg per deciliter (1.81 mmol per liter) -the most aggressive target specified by current lipid-lowering guidelines. During treatment, HDL cholesterol concentrations in both groups approached 50 mg per deciliterlevels currently considered acceptable for the secondary prevention of cardiovascular events. Both regimens had striking effects on coronary disease progression, resulting in significant regression of atherosclerosis. These data indicate that coronary artery disease can regress if the favorable levels of LDL and HDL cholesterol that were attained with statin therapy in this study are achieved. As compared with the ator va stat in regimen, the rosuvastatin regimen resulted in lower LDL cholesterol levels (a difference of −7.5 mg per deciliter [−0.19 mmol per liter]) and slightly higher HDL cholesterol levels (a difference of 1.8 mg per deciliter [0.05 mmol per liter]). These differences did not result in a significant incremental effect on disease regression, as assessed according to the primary intravascular ultrasonographic end point (PAV). These results may have been influenced by smaller-than-anticipated differences between the two groups with respect to HDL cholesterol levels. Rosuvastatin did show a significant benefit with respect to disease regression as assessed according to TAV, a secondary intravascular ultrasonographic end point, but the difference between the two regimens was relatively modest. These data show that the two regimens are similar in their ability to limit progression or induce regression of coronary disease, although a small difference in efficacy cannot be ruled out on the basis of the significant differences observed for the change in TAV. Our study shows that in appropriately selected patients, either regimen can be used to reduce the atheroma burden for the purpose of secondary prevention. * Plus-minus values are means ±SD. CI denotes confidence interval, PAV percent atheroma volume, and TAV total atheroma volume. † The P value for the between-group comparison of the change from baseline was calculated with the use of analysis of covariance, with the rate of change in PAV or in TAV as the independent variable and the rank of the corresponding baseline value as a covariate and treatment group as a factor.
The Overall, regression of atherosclerosis was observed in approximately two thirds of the study patients during 104 weeks of statin therapy. For the primary end point (PAV), a numerically higher percentage of rosuvastatin-treated patients had regression (68.5%, vs. 63.2% with ator va stat in), with a trend toward significance (P = 0.07). The frequency and extent of regression in both groups were unprecedented, as compared with the results of prior intravascular ultrasonographic studies. Previous studies have suggested an association between progression rates and cardiovascular outcomes, 29, 30 but the precise nature of the relationship remains a subject of ongoing research. Theoretically, regression involves reductions of the lipid, inflammatory, and necrotic components of plaque, each of which has been implicated in plaque rupture. Yet intravascular ultrasonography remains a surrogate end point, and a reduction in plaque volume should not be interpreted as equivalent to a clinical benefit in terms of preventing cardiovascular events. Furthermore, the clinical significance of regression or of observed differences in the secondary end point remains to be established. Despite these limitations, we consider the current evidence showing that the growth of atherosclerotic plaques can be reversed to be promising and deserving of further study in clinical trials.
The incidence of adverse effects accompanying the benefits observed in this trial was low. Increases in liver enzyme levels were more common in the ator va stat in group, with alanine aminotransferase levels that were more than 3 times the upper limit of the normal range in 14 patients, as compared with 5 patients in the rosuvastatin group (2.0% vs. 0.7%). Creatine kinase levels were more than 10 times the upper limit of the normal range in 4 ator va stat in-treated patients and in 1 rosuvastatin-treated patient, but in neither treatment group were there two consecutive increases in creatine kinase levels that were more than 5 times the upper limit of the normal range. Rhabdomyolysis was not observed in any patient. Proteinuria was more common in the rosuvastatin group than in the ator va stat in group (3.8% vs. 1.7%). Although the effect of statins on the incidence of diabetes has received considerable attention recently, neither treatment group had an increase in glycated hemoglobin levels. Taken as a whole, our findings indicate that intensive statin treatment led to disease regression with few adverse events.
Although the study was not powered to detect between-group differences in major adverse clinical events, these outcomes were adjudicated at a central site. The overall incidence of myocardial infarction was 1.6% during 24 months of followup, and the incidence did not differ significantly between the treatment groups. The rate of stroke was 0.4% and the rate of cardiovascular death was 0.3%, with no significant between-group differences in these rates. Only 0.5% of patients underwent coronary-artery bypass grafting, but 5.4% of patients underwent percutaneous coronary intervention, in most cases for restenosis involving lesions initially treated at the time of enrollment. These event rates are extremely low for a population with angiographically documented coronary disease and affirm that very intensive lipid-lowering with statins is associated with favorable clinical outcomes in a patient population at high risk. Although subgroup analyses do not furnish definitive evidence of benefit or harm, they may provide hypothesis-generating insights. Statistical evidence of heterogeneity showing benefit with rosu vastatin, the most useful measure of subgroup differences, was observed among women and among patients with higher baseline levels of LDL cholesterol. The greater benefit noted among patients with higher HDL cholesterol levels may reflect improved functional activity of HDL. The better response of patients with higher LDL cholesterol levels seems biologically plausible, since these patients may have greater benefits from a more effective LDL cholesterol-lowering regimen. Future analyses may yield useful insights into which of the effects of statin therapy -reductions in LDL cholesterol levels, increases in HDL cholesterol levels, nonlipid antiinflammatory effects, or a combination of effects -is associated with plaque regression.
Our findings have implications for the development of novel antiatherosclerotic therapies. The LDL cholesterol levels seen in this study are lower than those endorsed by current guidelines, providing a biologic foundation for future trials that target very low LDL cholesterol levels. The levels of LDL and HDL cholesterol observed in the current study cannot be achieved with statins alone in all patients with atherosclerotic coronary disease; however, LDL cholesterol-lowering therapies currently under development may result in these lipid levels in more patients. Furthermore, about one third of patients in our study had disease progression despite maximally intensive statin therapy. This finding suggests a potentially important role for novel agents designed to reduce LDL cholesterol levels, increase HDL cholesterol levels, or modify disease activity by means of other pathways. Indeed, a substantial residual risk of clinical events remains in most secondary-prevention populations despite the use of the most effective current medical therapies, affirming the need for new antiatherosclerotic agents.
This study has important limitations. It was not ethically possible to measure disease progression in placebo-treated patients. The trial involved patients undergoing clinically indicated coronary angiography. It remains uncertain whether our findings apply to primary prevention in asymptomatic patients. In trials that use intravascular ultrasonographic assessment of regression-progression, some patients elect not to undergo follow-up cardiac catheterization and therefore cannot be considered in the calculation of intravascular ultrasonographic end points. In the current trial, 25% of patients did not have intravascular ultrasonographic imaging that could be evaluated at follow-up, which was a smaller percentage than that reported in most contemporary trials. Patients who did not complete the trial may have had rates of progression that were different from those among patients who completed the trial. This study used intravascular ultrasonography to examine disease progression, but some newer analytic methods may permit the characterization of plaque constituents. Alternative therapies might have differing effects on plaque composition.
Statins have been among the most extensively studied classes of pharmacologic therapies. The findings have elucidated how these agents work and have expanded their potential clinical usefulness. Although the current comparative study does not show a significant difference between the treatment groups with regard to the primary end point, it does show that high-dose, intensive statin therapy can be administered safely and can promote regression of atherosclerotic plaque to a greater extent than has previously been reported. These findings represent a useful step forward in the effort to prevent the devastating clinical sequelae of atherosclerotic cardiovascular disease.
